A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 297, Issue 6, 2009, Pages

  Cheng, Long ^a   Han, Xiao ^b   Shi, Yuguang ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic retinopathy; Lysophosphatidylcholine; Lysophosphatidylcholine acyltransferase; Platelet activating factor

Indexed keywords

1 ACYLGLYCEROPHOSPHOCHOLINE ACYLTRANSFERASE; 1 O ALKYLGLYCERO 3 PHOSPHORYLCHOLINE; ACYL COENZYME A; ACYLTRANSFERASE; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE 1; MESSENGER RNA; ROSIGLITAZONE; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CATALYSIS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE MODEL; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; GENE EXPRESSION REGULATION; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; RETINA; UPREGULATION;

1-ACYLGLYCEROPHOSPHOCHOLINE O-ACYLTRANSFERASE; ACETYL COENZYME A; ANIMALS; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; COS CELLS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HYPOGLYCEMIC AGENTS; LYSOPHOSPHATIDYLCHOLINES; MALE; MICE; PLATELET ACTIVATING FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLIDINEDIONES; TRANSFECTION;

EID: 72249121427     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00475.2009     Document Type: Article

References (35)

1. Bazan HE, Hurst JS, Bazan NG. Differences in the acyl composition of the platelet-activating factor (PAF) precursor and other choline phosphoglycerides of the rabbit retinal rod outer segments and neural retina. Curr Eye Res 13: 45-50, 1994.
2. Beauchamp MH, Marrache AM, Hou X, Gobeil F Jr, Bernier SG, Lachapelle P, Abran D, Quiniou C, Brault S, Peri KG, Roberts J 2nd, Almazan G, Varma DR, Chemtob S. Platelet-activating factor in vasoobliteration of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 43: 3327-3337, 2002.
3. Cao J, Hawkins E, Brozinick J, Liu X, Zhang H, Burn P, Shi Y. A predominant role of acyl-CoA:monoacylglycerol acyltransferase-2 in dietary fat absorption implicated by tissue distribution, subcellular localization, and up-regulation by high fat diet. J Biol Chem 279: 18878-18886, 2004. (Pubitemid 38623315)
4. Cavallo-Perin P, Lupia E, Gruden G, Olivetti C, De Martino A, Cassader M, Furlani D, Servillo L, Quagliuolo L, Iorio E, Boccellino MR, Montrucchio G, Camussi G. Increased blood levels of plateletactivating factor in insulin-dependent diabetic patients with microalbuminuria. Nephrol Dial Transplant 15: 994-999, 2000. (Pubitemid 30410371)
5. Chandrasekher G, Ma X, Lallier TE, Bazan HE. Delay of corneal epithelial wound healing and induction of keratocyte apoptosis by plateletactivating factor. Invest Ophthalmol Vis Sci 43: 1422-1428, 2002. (Pubitemid 34462640)
6. Chen X, Hyatt BA, Mucenski ML, Mason RJ, Shannon JM. Identification and characterization of a lysophosphatidylcholine acyltransferase in alveolar type II cells. Proc Natl Acad Sci USA 103: 11724-11729, 2006. (Pubitemid 44182518)
7. de la Cruz JP, Moreno A, Ruiz-Ruiz MI, García-Campos J, Sánchez de la Cuesta F. Effect of WEB 2086-BS, an antagonist of plateletactivating factor receptors, on retinal vascularity in diabetic rats. Eur J Pharmacol 360: 37-42, 1998. (Pubitemid 28529394)
8. Dharma S, Bazan HE, Peyman GA, Atef MS. Production of plateletactivating factor in photocoagulated retinas. Curr Eye Res 10: 1031-1035, 1991.
9. Doly M, Cluzel J, Bonhomme B, Millerin M, Braquet P. Protective effect of a specific PAF antagonist on vincristine-induced experimental retinopathy. Acta Ophthalmol Scand 73: 155-157, 1995.
10. Ersoy B, Huseyinov A, Darcan S. The role of platelet-activating factor in pathogenesis of type 1 diabetes. Diabetes Care 28: 980, 2005. (Pubitemid 40434510)
11. Fang X, Gibson S, Flowers M, Furui T, Bast RJ, Mills G. Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. J Biol Chem 272: 13683-13689, 1997. (Pubitemid 27224802)
12. Galili O, Versari D, Sattler K, Olson M, Mannheim D, McConnell J, Chade A, Lerman L, Lerman A. Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am J Physiol Heart Circ Physiol 292: H904-H911, 2007. (Pubitemid 46246940)
13. Hallberg CK, Trocme SD, Ansari NH. Acceleration of corneal wound healing in diabetic rats by the antioxidant Trolox. Res Commun Mol Pathol Pharmacol 93: 3-12, 1996. (Pubitemid 26277463)
14. Harayama T, Shindou H, Ogasawara R, Suwabe A, Shimizu T. Identification of a novel noninflammatory biosynthetic pathway of platelet- activating factor. J Biol Chem 283: 11097-11106, 2008.
15. He J, Qiu Y, Yan Y, Niu Y. [Relationship between changes of phospholipid and lipid peroxide of erythrocyte membrane and diabetic retinopathy]. Zhonghua Yan Ke Za Zhi 34: 202-204, 1998.
16. Hishikawa D, Shindou H, Kobayashi S, Nakanishi H, Taguchi R, Shimizu T. Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversity. Proc Natl Acad Sci USA 105: 2830-2835, 2008. (Pubitemid 351723629)
17. Iwase M, Sonoki K, Sasaki N, Ohdo S, Higuchi S, Hattori H, Iida M. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis 196: 931-936, 2008.
18. Kudolo GB, Dorsey S, Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and type 2 diabetic subjects. Thromb Res 108: 151-160, 2002. (Pubitemid 36184651)
19. Kujiraoka T, Iwasaki T, Ishihara M, Ito M, Nagano M, Kawaguchi A, Takahashi S, Ishi J, Tsuji M, Egashira T, Stepanova IP, Miller NE, Hattori H. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res 44: 2006-2014, 2003. (Pubitemid 37356674)
20. Labonte E, Kirby R, Schildmeyer N, Cannon A, Huggins K, Hui D. Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia. Diabetes 55: 935-941, 2006. (Pubitemid 44100167)
21. Lee ES, Jiang J, Sund GC, Simonson WT, Graham J, Dietsch G, Schimpf B, Bieg S, Peterman G, Lernmark A. Recombinant human platelet-activating factor acetylhydrolase reduces the frequency of diabetes in the diabetes-prone BB rat. Diabetes 48: 43-49, 1999. (Pubitemid 29019351)
22. Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem 14: 3209-3220, 2007.
23. Motley E, Kabir S, Gardner C, Eguchi K, Frank G, Kuroki T, Ohba M, Yamakawa T, Eguchi S. Lysophosphatidylcholine inhibits insulin-induced Akt activation through protein kinase C-α in vascular smooth muscle cells. Hypertension 39: 508-512, 2002. (Pubitemid 34165174)
24. Nakanishi H, Shindou H, Hishikawa D, Harayama T, Ogasawara R, Suwabe A, Taguchi R, Shimizu T. Cloning and characterization of mouse lung-type acyl-CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1). Expression in alveolar type II cells and possible involvement in surfactant production. J Biol Chem 281: 20140-20147, 2006. (Pubitemid 44065788)
25. +- ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients. Diabetes 43: 915-919, 1994.
26. Rosenbaum JT, Angell E, Wilson D, Broquet C, Boney RS, Braquet P. Intravitreally injected platelet activating factor induces retinitis in experimental animals. Curr Eye Res 18: 342-348, 1999. (Pubitemid 29237876)
27. Rosenbaum JT, Boney RS, Samples JR, Valone FH. Synthesis of platelet activating factor by ocular tissue from inflamed eyes. Arch Ophthalmol 109: 410-413, 1991.
28. Sánchez-Quesada JL, Benítez S, Pérez A, Wagner AM, Rigla M, Carreras G, Vila L, Camacho M, Arcelus R, Ordóñez-Llanos J. The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity. Diabetologia 48: 2162-2169, 2005. (Pubitemid 41416930)
29. Serban M, Tanaseanu C, Kosaka T, Vidulescu C, Stoian I, Marta DS, Tanaseanu S, Moldoveanu E. Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus. J Cell Mol Med 6: 643-647, 2002. (Pubitemid 44146442)
30. Shi AH, Yoshinari M, Wakisaka M, Iwase M, Fujishima M. Lysophosphatidylcholine molecular species in low density lipoprotein of type 2 diabetes. Horm Metab Res 31: 283-286, 1999. (Pubitemid 29196820)
31. Shindou H, Hishikawa D, Nakanishi H, Harayama T, Ishii S, Taguchi R, Shimizu T. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:LYSO-PAF acetyltransferase. J Biol Chem 282: 6532-6539, 2007. (Pubitemid 47100867)
32. Shindou H, Shimizu T. Acyl-CoA:lysophospholipid acyltransferases. J Biol Chem 284: 1-5, 2009.
33. Soupene E, Fyrst H, Kuypers FA. Mammalian acyl-CoA: lysophosphatidylcholine acyltransferase enzymes. Proc Natl Acad Sci USA 105: 88-93, 2008.
34. Yoshinari M, Shi AH, Yoshizumi H, Wakisaka M, Iwase M, Fujishima M. Probucol reduces lysophosphatidylcholines in low-density lipoprotein. Eur J Clin Pharmacol 55: 787-792, 2000. (Pubitemid 30201759)
35. Zhao Y, Chen YQ, Bonacci TM, Bredt DS, Li S, Bensch WR, Moller DE, Kowala M, Konrad RJ, Cao G. Identification and characterization of a major liver lysophosphatidylcholine acyltransferase. J Biol Chem 283: 8258-8265, 2008.